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Bleeding from oesophageal varices, oesophageal ulcers or oesophagitis is occasionally massive and difficult
to control. Octreotide, a synthetic analogue ofsomatostin lowers portal pressure and collateral bloodflow
including that through varices, increases lower oesophageal sphincter pressure, and inhibits the gastric
secretion of acid as well as pepsin. Our current experience suggests it is effective in controlling acute
variceal haemorrhage. Therefore we have examined the efficacy of octreotide in the control of post-
sclerotherapy bleeding from oesophageal varices, oesophageal ulcers and oesophagitis. During the study
period 77 patients experienced a significant gastrointestinal bleed (blood pressure < 100 mm Hg, pulse >
100 beats per min or the need to transfuse 2 or more units of blood to restore the haemoglobin level)
following injection sclerotherapy of oesophageal varices. The source of bleeding was varices in 42
patients, oesophageal ulcers in 31 and oesophagitis in 4. All patients received a continuous intravenous
infusion of octreotide (50 lag/h) for between 40-140h. If bleeding was not controlled in the first 12h after
commencing octreotide hourly bolus doses (50 lag) for 24 h were superimposed on the continuous infusion.
Haemorrhage was successfully controlled by an infusion of octreotide in 38 of the 42 patients with
bleeding from varices, in 30 of 31 patients with oesophageal ulceration, and all patients with oesophagitis.
In the patient with persistent bleeding from oesophageal ulceration and in 2 of the 4 with continued
haemorrhage from varices, haemostasis was achieved by hourly boluses of 50 lag octreotide for 24h in
addition to the continuous infusion. No major complications were associated with octreotide administra-
tion. The results of this study clearly indicate that octreotide is a safe and effective treatment for the
control of severe haemorrhage after technically successful injection sclerotherapy.
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INTRODUCTION
Injection sclerotherapy is an effective treatment for the
control of acute variceal bleeding and for subsequent
obliteration of the varices. Localised rebleeding fol-
lowing injection sclerotherapy of oesophageal varices
can occur from 3 sources, the varices themselves, oeso-
phageal ulcers and oesophagitis. Persistent or early
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recurrent bleeding from the varices following injection
sclerotherapy is often substantial, and is independ-
ently associated with a poorer prognosis 1. In contrast,
bleeding from oesophageal ulcers or oesophagitis af-
ter injection sclerotherapy is usually minor, but can
occasionally be massive and difficult to control. We
have recently demonstrated that somatostatin is a very
effective and safe treatment for the control of recur-
rent bleeding following injection sclerotherapy from
the varices2, oesophageal ulcers and oesophagitis3.
Octreotide, a synthetic analogue of somatostatin, has
similar effects as the native hormone on portal pres-
sure4, azygos blood flow5’6 intravariceal pressure7, the
gastric secretion of pepsin and acid and on lower2 S.A. JENKINS et al.
oesophageal sphincter pressure9. These properties of
somatostatin are thought to be the main mechanisms
of action whereby the hormone is effective in control-
ling recurrent bleeding from varices, oesophageal
ulcers or oesophagitis after sclerotherapy. We have
therefore evaluated the efficacy of octreotide in the
management of post-sclerotherapy bleeding.
but in deep lesions a venous component could not be
excluded. The demographic data, grading ofthe sever-
ity according to the criteria of Childs’1, aetiology,
blood transfusion requirements, the duration of
octreotide therapy and the time interval between the
last sclerotherapy and onset of bleeding are shown in
Table 1.
PATIENTS AND METHODS
Between January 1989 and December 1992, 225 pa-
tients presenting with acute variceal haemorrhage,
were treated as an emergency, and 127 patients treated
electively on 519 occasions by injection sclerotherapy.
Injection sclerotherapy was carried out with a flexible
endoscope using an intravariceal technique of 2-3 ml
aliquots up to amaximum of20 ml at each session. On
some occasions however, the sclerosant was acciden-
tally injected paravariceally. If oozing persisted after
two 10 min periods oftamponade with the endoscope
or overtube, a Sengstaken tube was inserted for 12 h.
In patients with acute variceal haemorrhage, injection
sclerotherapy was repeated 5-7 days later provided
that there was no recurrent bleeding during the inter-
vening period. Elective sclerotherapy was then carried
out at 3-4 week intervals until the varices were obliter-
ated.
During the study period 42 patients experienced
significant recurrent bleeding from their varices,
(within 24 h following sclerotherapy), 31 from oeso-
phageal ulcers and 4 from oesophagitis. A significant
haemorrhage was defined as either haematemesis and
or melaena accompanied by either a systemic distur-
bance (systolic blood pressure less than 100 mm Hg
and a heart rate greater than 100 beats/min) requiring
blood tranfusion to maintain the vital signs, or the
necessity to transfuse 2 or more units of blood to
restore the haemoglobin levels. To the prehaemorrage
levels. In all patients the site of haemorrhage was
confirmed endoscopically, apart from those who bled in
the first 24 h after sclerotherapy. In these patients the
site of haemorrhage was assumed to be from the
varices since oesophageal ulceration and oesophagitis
after sclerotherapy take longer to develop. The ab-
sence of oesophagitis, oesophageal ulceration and
other sources of recurrent bleeding determined by
repeat endoscopy, carried out after cessation of
octreotide therapy, confirmed the diagnosis of recur-
rent variceal haemorrhage. In no patient bleeding
from oesophageal ulcers or oesophagitis could a
variceal component to the haemorrhage be.detected,
Octreotide treatment
Initially, all patients with recurrent bleeding from
varices, oesophageal ulcers or oesophagitis were trea-
ted with a continuous infusion of 50 gg/h octreotide. If
bleeding was not controlled in the first 12 h of treat-
ment the patients were given hourly bolus injections of
octreotide (50 gg) for 24 h in addition to the continu-
ous infusion.
Success oftreatment
Successful control of haemorrhage was defined as the
cessation of bleeding, as confirmed by the absence of
overt signs and the stabilisation of the haemoglobin
levels, without the need for blood transfusion.
RESULTS
Recurrent variceal bleeding
During the study period a total of 744 courses of
sclerotherapy were carried out, 225 to control an acute
variceal bleed and 519 electively. Continued or early
recurrent bleeding from varices occurred in 42 patients
following sclerotherapy, an incidence of 5.6%. The
incidence of recurrent variceal bleeding was much
higher after emergency sclerotherapy (40/225; 18%)
than following an elective session (2/519; 0.4%).
In the 42 patients who rebled following sclero-
therapy the sclerosant had been administered intrava-
riceally in 36 and paravariceally in 6 at the session
preceding their recurrent haemorrhage. The volume of
ethanolamine injected in patients who subsequently
rebled (median 10, range 3-18 ml) was not signifi-
cantly different from that administered to patients
who did not rebleed (median 8.5, range 2-20 ml).
A continuous infusion of octreotide controlled per-
sistent or recurrent variceal bleeding in 38/42 (90.5%)
patients (Table 2). In four patients with severe liver
disease (Child’s C) bleeding was not controlled during
the first 12 h of octreotide infusion as indicated by
continued haematemesis and/or melaena accompa-
nied by a systemic disturbance, and the need toPOST-SCLEROTHERAPY HAEMORRHAGE 3
Table 1 Demographic data, aetiology and severity of liver disease, duration of octreotide therapy and
time interval between the last sclerotherapy in patients bleeding from varices, oesophageal ulcers or
oesophagitis following sclerotherapy
Source of bleeding Varices Oesophageal Ulcers Oesophagitis
Age range (median) years
Male/Female
Aetiology of liver disease
Alcohol
Alcohol plus hepatocellular
carcinoma
Cryptogenic
Chronic active hepatitis
Primary biliary cirrhosis
Idiopathic
Haemochromatosis
Child’s grade
A
B
C
Time to onset of bleeding
after sclerotherapy
(range;median) days
Details of sclerotherapy prior to bleeding
Volume of sclerosant
(range:median)
Intravariceal injections
Paravariceal injections
Mixed
Blood transfusion requirements (units)
Before octreotide treatment
(range:median)
During octreotide treatment
(range:median)
Duration of octreotide therapy h
(range:median)
21-73; 54.5 30-76; 59 63-79; 71
28:14 20:1 4:0
34 26 2
0 0
3 2 2
0
2 0
0 0
0 0
3 2
9 3 2
32 25 0
0-72; 14.5 2-29; 9 10-171; 75
3-18; 10 4-18; 9 2-9; 8
36 11 0
0 2
6 19 3
3-13; 3.5 3-9;5 4-8; 5.5
1-7; 2.5 1-4; 2 1-4; 2
40-140; 80 40-120; 80 80-140; 120
Table 2 Efficacy of octreotide in controlling post-sclerotherapy bleeding from
oesophageal varices, oesophageal ulcers and oesophagitis
Source ofbleeding Control ofbleeding
Octreotide Octreotide infusion
infusion plus hourly 50 tg
(50 tg/h) bolus dosesfor 24h
Hospital Mortality
Oesophageal varices 38/42 (90.5%) 2/4
Oesophageal ulcers 30/31 (97%) 1/1
Oesophagitis 4/4 (100%)
8/42 (19%)
3/31 (9.7%)
0/4
transfuse blood to maintain the haemoglobin level. In
two ofthese patients bleeding was controlled by giving
hourly bolus doses of 50 gg octreotide in addition to a
continuous infusion. Thus, overall control of bleed-
ing was achieved in 40/42 (95%) patients treated
with octreotide. The two patients who failed
octreotide therapy continued to bleed despite fur-
ther sclerotherapy and balloon tamponade, and
haemorrhage was eventually controlled by emer-
gency oesophageal transection. However, both pa-
tients developed hepatorenal syndrome following
operation and died.
Recurrent bleeding did not occur in any of the 40
patients after cessation of octreotide therapy and 33
were discharged from hospital. Six patients, all with
severe liver disease on admission and all presenting
with an acute variceal bleed, died (liver failure n 3,
hepatorenal syndrome N 3) in hospital. Thus, the
overall hospital mortality was 8/42 (19%).
Oesophageal ulceration
Severe bleeding from oesophageal ulceration occurred
in 31 patients, an overall incidence of 4.1% The4 S.A. JENKINS et al.
incidence ofsevere bleedingfrom oesophageal ulceration
was lower after a single course of sclerotherapy to
control a variceal bleed (1/225; 0.4%) than after ele-
ctive sclerotherapy (30/519; 5.8%). In all patients apart
from one who bled 29 days after the previous session
of sclerotherapy, the varices were patent at the diag-
nostic endoscopy, but in no case was a variceal compo-
nent to the bleeding observed. However, in all these
patients the possibility that there were communicating
vessels between the ulcers and either the varices or the
complex arrangement of blood vessels in or around
the oesophagus cannot be discounted.
In the 31 patients who bled from oesophageal ulcers,
the sclerosant was administered intravariceally in 11,
paravariceally in and both intravariceally and para-
variceally in 19 at the sclerotherapy session preceeding
their haemorrhage. The volume of sclerosant injected
in the patients who subsequently bled from their oeso-
phageal ulcers (median 9, range 2-20 ml) was not
significantly different from that injected in patients
who did bleed from oesophageal ulcers (median 8,
range 2-19 ml).
A continuous infusion of octreotide (50 tg/h) con-
trolled appreciable bleeding from oesophageal ulcers
in 30/31 (97%) patients. In the one patient in whom
bleeding persisted, control of haemorrhage was
achieved by hourly bolus doses of 50 tg octreotide
superimposed on their continuous infusion (Table 2).
Bleeding did not recur in any of the patients following
cessation of octreotide treatment, and 28 were dis-
charged from hospital. However 3 patients, all with
severe liver dysfunction (Child’s C) and alcoholic
liver disease died, one from liver failure and two from
the hepatorenal syndrome.
Oesophagitis
Appreciable bleeding from oesophagitis occurred only
in 4 patients and in each case followed elective injection
sclerotherapy. Thus the incidence of appreciable bleed-
ing from oesophagitis after sclerotherapy was 0.54%.
In 3 patients, bleeding from oesophagitis after
sclerotherapy occurred much later than that from the
varices or oesophageal ulcers (Table 1). At endoscopy,
3 ofthe patients had obliterated varices, and one had a
single small patent varix. All patients had undergone
numerous courses of injection sclerotherapy (median
7, range 5-14). At the endoscopy prior to presenting
with appreciable bleeding from circumferential
oesophagitis affecting the distal 5cm of the oesopha-
gus, the sclerosant was injected paravariceally in and
both intravariceally and paravariceally in 3. The
amount of ethanolamine injected in the patients who
bled from oesophagitis (median 8, range 2-9) was less
than in those who did not bleed from oesophagitis
(median 10, range 2-20). Early rebleeding after scler-
otherapy (10 days) occurred in one patient who had
received only paravariceal administration of sclero-
sant at the endoscopy prior to the development of
haemorrhagic oesophagitis.
Octreotide infusion successfully controlled the
bleeding in all 4 patients bleeding from oesophagitis
(Table 2). No further bleeding occurred after cessation
of octreotide treatment and all 4 patients made an
uneventful recovery and were discharged home on
ranitidine and gaviscon.
DISCUSSION
The incidence of recurrent variceal bleeding following
injection sclerotherapy observed in this study is
similar to that of previously reported series1. Balloon
tamponade is widely used to control recurrent variceal
bleeding following sclerotherapy. However, balloon
tamponade is associated with serious side effects, in-
cluding oesophageal ulceration and perforation in
10-25% ofpatients when used as a stop-gap therapy to
control bleeding before definitive therapy2. Following
sclerotherapy, the risk of balloon tamponade pro-
ducing perforation or ulceration of the oesophagus
may be increased, because of the damaging effects of
the sclerosant on the oesophageal mucosa 13. Conse-
quently, it has been suggested that the period of bal-
loon tamponade should be limited to a period of 12 h
after sclerotherapy to minimise the risk of local com-
plications12. If bleeding persists following a 12 h period
of balloon tamponade treatment can be problemati-
cal. Further periods of tamponade may control
bleeding but the complication rate can become unac-
ceptably high. Similarly, a second course of sclero-
therapy may control bleeding, but in those patients in
which it is not successful, the mortality approaches
100% TM. Furthermore emergency oesophageal tran-
section is often unrewarding because of difficulty in
mobilising the oesophagus after injection sclerothe-
rapy
4 and the high mortality associated with surgical
intervention in patients with poor liver function 15. We
have recently demonstrated that somatostatin is a
very effective and safe treatment for the control of
recurrent variceal bleeding following sclerotherapy2.
The results of the present study in a much larger
number of patients suggest that octreotide is
equally as effective as somatostatin in controllingPOST-SCLEROTHERAPY HAEMORRHAGE 5
post-sclerotherapy variceal bleeding. Furthermore, no
complications were associated with octreotide therapy.
In 2 of the 4 patients in whom octreotide failed to
control haemorrhage, haemostasis was achieved by
administering hourly bolus doses of octreotide for
24 h, in addition to the continuous infusion. The ra-
tionale for this treatment was based on observations in
the portal hypertensive cirrhotic rat which suggested
that bolus administrations of somatostatin reduced
portal pressure and collateral blood flow to a greater
extent than a continuous infusion17’18, observations
recently confirmed in man19. Therefore, bolus injec-
tions of octreotide together with a continuous infusion
of octreotide, could possibly reduce collateral blood
flow to a greater extent than an infusion alone and
thus facilitate control of bleeding. This suggestion is sup-
ported to some extent in this study, since 2 of the 4
patients stopped bleeding during their treatment with
hourly bolus doses of octreotide superimposed on a
continuous infusion.
Severe bleeding from oesophageal ulcers or oeso-
phagitis following injection sclerotherapy is perhaps
more problematical than that of recurrent variceal
haemorrhage, since there are fewer treatment options
available. Balloon tamponade is contraindicated in
these circumstances since pressure necrosis may
exacerbate the ulceration or oesophagitis, whilst oeso-
phageal transection is difficult and unrewarding in
patients with poor liver function15’6. Consequently,
effective drug therapy is required to control bleeding
from these sources. We have demonstrated that
somatostatin is a very effective and safe treatment
for the control of severe bleeding from post-sclero-
therapy oesophageal ulceration and oesophagitis3.
The results of this study indicate that an infusion
of 50 lag/h octreotide is equally as effective as
somatostatin in these indications, controlling bleed-
ing in all 4 patients with oesophagitis and 30/31
patients with oesophageai ulceration. Furthermore,
in the patient with oesophageal ulcers who con-
tinued to bleed during octreotide infusion, addition of
hourly boluses of the somatostatin analogue for 24
controlled haemorrhage. This observation further sup-
pors the suggestion that bolus doses of octreotide
superimposed on a continuous infusion may be useful
in controlling persistent bleeding, possibly by reduc-
ing collateral blood flow to a greater extent than an
infusion alone. No major side-effects were associated
with octreotide administration, with the exception of
one patient who experienced a marked increase in the
plasma levels of bilirubin and liver enzymes. Following
oessation of octreotide administration in this pa-
tient the plasma levels of bilirubin and liver enzyme
gradually returned to pre-treatment levels.
Although reports on the effects of octreotide on
portal pressure have provided conflicting results, the
analogue has been consistently demonstrated to lower
azygos blood flow5’6. Furthermore, octreotide reduces
azygos blood flow to a greater extent than it reduces
portal pressures’8. Consequently, the reduction in azy-
gos blood flow, indicative of a reduction in collateral
blood flow including that through the varices, may be
the most important determinant in controlling vari-
ceal bleeding. A reduction in collateral blood flow,
including that through the complex venous network in
the lamina propria of the oesophagus, may also be a
major factor in controlling bleeding from post-sclero-
therapy ulcers and oesophagitis. In portal hyperten-
sion, the 4 layers of veins of the lower oesophagus are
grossly dilated, and the large intrinsic vessels which
form the varices communicate directly or indirectly
with all the remaining venous channels2. It is there-
fore impossible to exclude a venous component to the
haemorrhage from oesophagitis or oesophageal ulcers
after sclerotherapy, since it seems likely that there are
communications between these lesions, and other ve-
nous components of the oesophagus or peri-oesopha-
geal veins. Thus although bleeding could be observed
from oesophageal ulcers or from the friable mucosa in
oesophagitis and not from the varices, it is not possible
to exclude a venous component to the haemorrhage,
and a reduction in blood flow through these vessels
elicited by octreotide may be an important factor in
controlling haemorrhage from these lesions. The pre-
cise mechanism whereby octreotide decreases collat-
eral blood flow is unknown, but may be mediated
directly by eliciting vasoconstriction through specific
receptors in these vessels2. Alternatively, octreotide
may reduce collateral blood flow via inhibition of the
release of vasoactive substances responsible for the
hyperdynamic circulation in portal hypertensive
patients2. Finally, by increasing lower oesophageal
pressure octreotide may decrease blood flow through
complex venous network of the lower oesophagus.
Following initial control of haemorrhage, octreo-
tide has other effects which may be beneficial in pre-
venting recurrent bleeding. Although erosion of the
varices by reflux of gastric contents is not thought to
contribute to variceal bleedingper se, it may, by disso-
lution of the fibrin plug or clot at the site of haemo-
stasis, precipitate further bleeding. Octreotide by
inhibiting the secretion of gastric acid and pepsin and
by increasing lower oesophageal sphincter pressure,
may reduce the volume and digestive capacity of any6 S.A. JENKINS et al.
refluxed material, and thereby minimise risk of clot or
fibrin plug dissolution and hence rebleeding.
In summary, the results of this study that octreotide
is an effective treatment for post-injection sclero-
therapy bleeding from oesophageal varices or ulcers
and oesophagitis. These encouraging observations re-
quire confirmation in randomised controlled trials.
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